Search
Ironwood Pharmaceuticals Inc
IRWDAdd to Watchlist
4.190USD
-0.080-1.87%
Close 09-23 16:00（ET）
689.72MMarket Cap
6.65P/E TTM
About Ironwood Pharmaceuticals Inc Company
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Ironwood Pharmaceuticals Inc Profile
Ticker SymbolIRWD
Company nameIronwood Pharmaceuticals Inc
IPO dateFeb 03, 2010
CEOMccourt (Thomas A)
Number of employees253
Security typeOrdinary Share
Fiscal year-endFeb 03
Address100 Summer Street, Suite 2300
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02110
Phone16176217722
Websitehttps://www.ironwoodpharma.com/
Ticker SymbolIRWD
IPO dateFeb 03, 2010
CEOMccourt (Thomas A)
Company Executives of Ironwood Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
428.32K
+31.89%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Mr. Ronald Silver
Mr. Ronald Silver
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
271.90K
-47.04%
Mr. Ronald Silver
Mr. Ronald Silver
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
271.90K
-47.04%
Mr. Ronald Silver
Mr. Ronald Silver
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
271.90K
-47.04%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
428.32K
+31.89%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
FAQs
Who are the top five shareholders of Ironwood Pharmaceuticals Inc?
The top five shareholders of Ironwood Pharmaceuticals Inc are: Dr. Mark G. Currie, Ph.D.
How many institutions hold shares of Ironwood Pharmaceuticals Inc (IRWD)?
As of 2026Q1, 549 institutions hold shares of Ironwood Pharmaceuticals Inc, with a combined market value of approximately 166.41M, accounting for 101.09% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -30766447.00.